Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.
about
Plasmapheresis in immunologic renal diseaseBench-to-bedside review: Pulmonary–renal syndromes – an update for the intensivistWhat is new in the management of rapidly progressive glomerulonephritis?Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue.Crescentic glomerulonephritis: data from the Spanish Glomerulonephritis Registry.Guideline on the clinical use of apheresis procedures for the treatment of patients and collection of cellular therapy products. British Committee for Standards in Haematology.Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures.[Plasma exchange and immunoadsorption].Thrombotic thrombocytopenic purpura in a patient with rapidly progressive glomerulonephritis with both anti-glomerular basement membrane antibodies and myeloperoxidase anti-neutrophil cytoplasmic antibodies.Plasma exchange for renal disease: evidence and use 2011.Efficacy and safety of alemtuzumab in multiple sclerosis and impact on nursing role.Anti-hLAMP2-antibodies and dual positivity for anti-GBM and MPO-ANCA in a patient with relapsing pulmonary-renal syndrome.Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption.Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Role of therapeutic apheresis and phlebotomy techniques in anaesthesia and critical care.Identical twins:one with anti-glomerular basement membrane glomerulonephritis,the other with systemic lupus erythematosus.Pulmonary-renal vasculitic disorders: differential diagnosis and management.Maternal, pregnancy and fetal outcomes in de novo anti-glomerular basement membrane antibody disease in pregnancy: a systematic review.Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis.Anti-GBM disease with a mild relapsing course and low levels of anti-GBM autoantibodies.65-year-old woman with shortness of breath and dark urine.Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression.Zebrafish to humans: evolution of the alpha3-chain of type IV collagen and emergence of the autoimmune epitopes associated with Goodpasture syndrome.The role of plasmapheresis in critical illness.Indications for plasma exchange in systemic lupus erythematosus in 2005.Goodpasture's Disease: An Uncommon Disease With an Atypical Clinical CourseProteolysis breaks tolerance toward intact α345(IV) collagen, eliciting novel anti-glomerular basement membrane autoantibodies specific for α345NC1 hexamers.Current pharmacotherapy for the treatment of crescentic glomerulonephritis.Plasma exchange in Goodpasture syndrome associated with Turner's syndrome: A case reportSerum-starved adipose-derived stromal cells ameliorate crescentic GN by promoting immunoregulatory macrophages.An 80-year-old female with double positive disease: Case report and brief review of literature.Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Quaternary epitopes of α345(IV) collagen initiate Alport post-transplant anti-GBM nephritisAnti-neutrophil cytoplasmic (ANCA) and anti-glomerular basement membrane (GBM) autoantibodies in necrotizing and crescentic glomerulonephritis.A primer on recurrent and de novo glomerulonephritis in renal allografts.Multiple recurrences of anti-glomerular basement membrane disease with variable antibody detection: can the laboratory be trusted?Goodpasture Syndrome Diagnosed One Year And A Half after the Appearance of the First Symptoms (Case Report).Rituximab therapy in pemphigus and other autoantibody-mediated diseases.Anti-glomerular basement membrane disease: Case series from a tertiary center in North India.
P2860
Q27027106-C4DE08A7-2C13-4713-8C76-94613279A66EQ27485164-FBA60613-85A6-403C-8ED6-44A357B6871AQ28259540-974AD4A7-9F47-42F2-9D57-007ED544667AQ30276550-543EB1D3-E1A0-4B02-B229-598D2DD4A703Q30893344-DA7E8C48-F84B-45CF-90BC-FFABE1E8273EQ33165774-0F23D15E-3D9A-4C48-8134-B58E3F4FCB50Q33376371-D5EB348B-0617-41D6-A700-66B1580BF2C7Q33377027-A6E4F5DD-7DB8-4154-AB47-7EC72459223FQ33390757-E372A81A-69AF-4C76-A711-E55C25DDF641Q33400941-9A1FFE92-2DE1-41DA-8B8A-D3C659C57F69Q33412834-E88EA7B1-5B22-44F2-A627-2190EC68D160Q33926075-24FF858A-5059-4E76-A426-4A0EC3B03B59Q33982143-CD45894F-BEC5-4807-97DA-0E9D8635E42CQ34021733-28B4E00D-E031-4AF1-9083-E521FBDBE198Q34122035-8F392FAC-4CFD-4B1A-B0BD-756D4FE06597Q34659824-CCA2F0C8-9AE7-42DE-A67D-5EA8DBA77774Q35073646-89A55E70-042D-4D10-A064-4C495138637AQ35081998-7616C8DD-CB3A-43AD-9FD6-AC9A322F378BQ35232146-A0D2EDFA-AD50-4560-AAA0-1CB58F0C5A02Q35404631-C09F8613-8F86-4B4B-BC96-E6582D38AE2BQ35452904-8D7499EB-A394-461E-A3D7-E37FE9869722Q35671818-DF5F8014-761E-42B9-8B62-36A2F2BA12D8Q35809151-CAF225E1-0B26-40E1-B344-C64BCB7125A4Q35849436-485CC5FA-DE39-4C3E-98AD-FE799ECEDE16Q36053839-2F8AA9ED-1466-4908-8369-593E73D5F0F2Q36334472-5BDF1412-875F-4AD0-ADC6-C4030CDA47AFQ36364772-A8AD26CB-C4A9-4E21-8E0F-62DBD6175C28Q36586328-9EFCEA76-9CE6-4305-97CB-B531C092FDD2Q36623061-9FB21BD8-692E-407F-8AC4-E86BBB20A727Q36686665-5C79CE22-09DA-4ED5-A21C-427E842E3396Q36719227-95953C90-0B38-4B54-83AC-3E76713E21ECQ36734507-9376BF5D-89BF-42C1-89D1-297DC474C183Q36774059-017B29C7-F25B-4752-9AA0-6C4CDF147097Q36880447-404975E3-AA0C-4B4F-B688-F95DB97D8DCDQ36974296-2CA959A4-9F25-44C7-B469-6EB063FC4B71Q37193631-7012D4A4-EADC-4390-998A-2D9B55A69FCEQ37284106-74EE2C22-8263-4B1E-856E-A58E3FA8D733Q37523623-F06B67F2-F9C7-47B9-8C0F-C94A06813C6BQ37620483-400A30F9-BD3E-4893-B85E-4A6909D8F83BQ37711277-A0FA7F9E-A458-4262-B295-84EC31834ACF
P2860
Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Long-term outcome of anti-glom ...... xchange and immunosuppression.
@ast
Long-term outcome of anti-glom ...... xchange and immunosuppression.
@en
type
label
Long-term outcome of anti-glom ...... xchange and immunosuppression.
@ast
Long-term outcome of anti-glom ...... xchange and immunosuppression.
@en
prefLabel
Long-term outcome of anti-glom ...... xchange and immunosuppression.
@ast
Long-term outcome of anti-glom ...... xchange and immunosuppression.
@en
P2093
P1476
Long-term outcome of anti-glom ...... xchange and immunosuppression.
@en
P2093
P304
P356
10.7326/0003-4819-134-11-200106050-00009
P407
P577
2001-06-01T00:00:00Z